Full Press Release Details
Weill Medical College of Cornell University and Memorial Sloan Kettering Cancer Center - Chief Medical Officer of Kroger Health since 2018 - Previously served 5+ years in senior medical oversight roles at Concentra, as well as Interim Medical Director for the North American division of Nissan Motor Co. - Previously served as senior medical officer at a US Marine Corps Station, as well as group surgeon of Camp Al Asad in Iraq - Former adjunct professor in the pharmacy department of the University of Cincinnati 2024 Concentra Inc.
Thomas Director Keith Newton Director, CEO Cheryl Pegus, MD, MPH Director Marc R. Watkins, MD Director - Former Concentra President, CEO and COO from 1993 through 2007 - Director of Select Medical, Healthcare Highways, National Partners in Healthcare and Equalis Group; previously served on the board of AccentCare - Former executive roles with National Partners in Healthcare, Provista and Viant - Has served as Concentra's CEO since 2015 - Formerly Concentra's Chairman of the Board of Directors from 2018 to 2022; initially joined Concentra's predecessor, OccuSystems, in 1995 - Former executive roles with DentalOne Partners and Columbia HCA's Ambulatory Surgery Division, as well as accounting and finance roles at The Associates First Capital Corporation and KPMG Peat Marwick - Currently serves as a board member for Boston Scientific - Formerly served as a cardiovascular-focused medical director at Pfizer, partner at Morgan Health, Executive Vice President of Health and Wellness at Walmart, and Chief Medical Officer at Symcare Personalized Health Solutions and at Walgreens Company - Previously a cardiologist, clinical researcher and fellow at The Joan & Sanford I.
NEWTON Chief Executive Officer Joined Concentra (formerly known as OccuSystems) in 1995 40+ years of experience in healthcare business Tenure: 25 years JOHN DELORIMIER Executive Vice President, Chief Digital & Data Officer Tenure: 16 years DANIELLE KENDALL Senior Vice President, Human Resources Tenure: 24 years JONATHAN CONSER Executive Vice President, Chief Growth & Customer Officer Tenure: 21 years DOUGLAS MCANDREW Executive Vice President, Chief Operating Officer West Tenure: 30 years GIOVANNI GALLARA, PT Executive Vice President, Chief Clinical Services Officer Tenure: 13 years JOHN ANDERSON, DO Executive Vice President, Chief Medical Officer Tenure: 31 years GREG GILBERT Executive Vice President, Chief Reimbursement & Government Relations Officer Tenure: 30 years SU ZAN NELSON Executive Vice President, Chief Accounting Officer Tenure: 21 years MICHAEL KOSUTH Executive Vice President, Chief Operating Officer East Tenure: 28 years MICHAEL RHINE Executive Vice President, Chief Operating Officer Onsite Health & Telemedicine Tenure: 21 years THOMAS DEVASIA Executive Vice President, Chief Marketing & Innovation Officer Tenure: 8 years TIM RYAN Executive Vice President, General Counsel Tenure: Joined Oct. 2024 2024 Concentra Inc.
Comp. Empl. Svcs. Cons. Health +2% -5% -2% $1,397.3 $1,435.2 YTD '23 YTD '24 +3% Revenue ($mm) $293.0 $299.3 YTD '23 YTD '24 +2% Adjusted EBITDA1 ($mm) 21.0% 20.9% YTD '23 YTD '24 -10bps Adjusted EBITDA Margin1 $134.62 $140.12 YTD '23 YTD '24 +4% Work. Comp. Empl. Svcs. $195 $86 $199 $90 +2% +4% Number of Locations Visits per Day Revenue per Visit 2024 Concentra Inc.
Includes wage and productivity losses of $50.7 billion, medical expenses of $37.6 billion, administrative expenses of $54.4 billion, employers' uninsured costs of $15.0 billion, damage to motor vehicles in work-related injuries of $5.6 billion and fire losses of $3.7 billion; (7) Includes wage and productivity losses of $50.7 billion, administrative expenses of $54.4 billion, employers' uninsured costs of $15.0 billion, damage to motor vehicles in work-related injuries of $5.6 billion and fire losses of $3.7 billion 12 High injury rates among young workers 28% Of claims attributable to manufacturing employees with <1 year experience3 Aging employed population 25-30% Of U.S. employees projected to be over age 55 by 20301 Prevalence of depression and anxiety 50% Of injured employees experience clinically-related depressive symptoms5 Inadequate cost-effective solutions $167bn Total cost of work-related injuries in 2022 in the U.S.6 Widespread hazardous exposures 40mm Employees potentially exposed to hazardous chemicals in the workplace4 Increase in comorbidity claims 175% Increase in workers' compensation claims involving comorbidities2 $167bn Medical Expenses Other Expenses7 - Wage and Productivity Losses - Administrative Expenses - Employers' Uninsured Costs - Other Losses ~$129bn (~77% of total) ~$38bn (~23% of total) 2024 Concentra Inc.
See the Appendix for a reconciliation of TTM 4 Concentra is the largest provider of occupational health services in the United States by number of locations1 , with a mission of improving the health of America's workforce, one patient at a time. KEY STATISTICS 156 Onsite health clinics1 ~11k Total colleagues & affiliated clinicians2,3 $1.9bn TTM Revenue1,6 19.6% TTM Adj.
Because Adjusted EBITDA and Adjusted EBITDA margin are not measurements determined in accordance with U.S. GAAP and are thus susceptible to varying definitions, Adjusted EBITDA and Adjusted EBITDA margin as presented may not be comparable to other similarly titled measures of other companies. We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries.
Adjusted EBITDA and Adjusted EBITDA margin should not be considered in isolation, or as an alternative to, or substitute for, net income, net income margin, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity.
Adjusted EBITDA and Adjusted EBITDA margin are used by management to evaluate financial performance of, and determine resource allocation for, each of our operating segments. However, Adjusted EBITDA and Adjusted EBITDA margin are not measures of financial performance under U.S. GAAP. Items excluded from Adjusted EBITDA and Adjusted EBITDA margin are significant components in understanding and assessing financial performance.
This information can be accessed for free by visiting www.concentra.com or www.sec.gov. We believe that the presentation of Adjusted EBITDA and Adjusted EBITDA margin, as defined herein, are important to investors because Adjusted EBITDA and Adjusted EBITDA margin are commonly used as an analytical indicator of performance by investors within the healthcare industry.
Use of Non-GAAP Financial Information In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision making, the Company supplements its condensed consolidated financial statements presented on a GAAP basis herein with certain non-GAAP financial information, including reconciliations of these non-GAAP measures to their most directly comparable GAAP measures, which are included in this presentation, as well as in the Company's quarterly financial press releases and related Form 8-K filings with the SEC.
Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date made. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Company's filings with the Securities and Exchange Commission ( SEC ), including those under Risk Factors therein.